ArticleEJHaem2026
Understanding Treatment Care and Delays in Acquired Hemophilia A: A Population-Based Study From Nova Scotia, Canada.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Acquired Hemophilia A (AHA) is a rare, potentially life-threatening bleeding disorder caused by autoantibodies against factor VIII (FVIII). We aimed to characterize patients with AHA in Nova Scotia, Canada, and assess diagnostic delays. Methods: We conducted a retrospective, population-based study of adults (≥ 18 years) with AHA treated at the central Hemophilia Treatment Center (HTC) from 2006 to 2024. Demographics, presentation, treatment, outcomes, and diagnostic timelines were reviewed. Results: Twenty-seven cases were identified, with a mean annual incidence of 1.46 per million. Median age was 74 years (Interquartile range [IQR] 63.5-80); 26% had malignancy and 22% autoimmune disease. All patients received immunosuppressive therapy, and 63% required bypassing agents. Relapsing or refractory disease occurred in 30%. The 5-year overall survival was 48%. Diagnosis was delayed ≥ 7 days in 63% of cases, with median times of 32 days (IQR 4.5-75) from first bleeding and 10 days (IQR 6-45.5) from first elevated PTT. Patients had a median of 2 (IQR 2-5) bleeding-related encounters before diagnosis. Delayed diagnoses were linked to younger age, disease severity, and rural residence. Conclusion: Despite centralized care, diagnostic delays were frequent, underscoring the need for early coagulation testing in unexplained bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.